Munich — Start-up Nera­Care GmbH, a specia­list in skin cancer risk assess­ment, has secu­red EUR 8 million in a Series A finan­cing round. MIG Funds 10, 14 and 16, BayBG Baye­ri­sche Betei­li­gungs­ge­sell­schaft and Synvie GmbH parti­ci­pa­ted in the finan­cing round. LUTZ | ABEL as legal advi­sor to the inves­tors MIG-Fonds and BayBG Baye­ri­sche Betei­li­gungs­ge­sell­schaft has the lead in this Series‑A finan­cing round.

The round was led by MIG Fonds 10, 14 and 16 — other inves­tors include BayBG Baye­ri­sche Betei­li­gungs­ge­sell­schaft and Synvie GmbH. Nera­Care is active in the field of precis­ion medi­cine against black skin cancer, defen­ding its unique posi­tion. The start-up deve­lops and markets gene expres­sion tests to deter­mine the risk of recur­rence in mali­gnant mela­n­oma. With the help of such a mela­n­oma diagno­sis, doctors will be able to make a relia­ble progno­sis in the future and make infor­med treat­ment decis­i­ons: Pati­ents with low-risk tumors will thus be spared unneces­sary drug thera­pies, while those pati­ents with incon­spi­cuous but higher-risk tumors and ther­e­fore more in need of treat­ment can be identified.

LUTZ | ABEL provi­ded compre­hen­sive advice on the finan­cing round.
Dr. Bern­hard Noreisch (VC/M&A, Munich) was the lead part­ner. The teams also included: Jan-Phil­lip Kunz (VC/M&A, Munich), Dr. Sebas­tian Sumal­vico (VC/M&A, Munich), Cars­ten Huch-Hall­wachs (IP, Munich) and Andreas Kössel (Labor Law, Munich). Nera­Care GmbH was advi­sed by Honert (Sven Frit­sche, Kai-Clemens Wehlage), the foun­ders were advi­sed by CMS (Dr. Tilman Weichert) and the manage­ment by Diss­mann Orth (Dr. Martin Lohse). The inves­tor Synvie GmbH was advi­sed by Pinsent Masons (Chris­tian Lang).